This subtype of RCC in adults requires special attention and more intensive studies for its rarity, aggressiveness in nature, and possible different treatment options (e.g., mTOR inhibitors or VEGF-targeted agents) [3, 8, 11, 12]. Here, VEGFA is linked to renal cell carcinoma.